Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...
4hon MSN
Eli Lilly ( LLY 2.11%) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive ...
Eli Lilly (LLY) announced the launch of 7.5 mg and 10 mg Zepbound single-dose vials, available for $499 with the new Zepbound Self Pay Journey ...
Eli Lilly kicks off 2025 with key licensing deals and M&A, boosting its position across therapeutic areas amid rising drug ...
Whales with a lot of money to spend have taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli ...
Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...
Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes ...
Eli Lilly (LLY, Financial) is set to pivot its focus beyond obesity after a monumental windfall from its GLP-1 drugs. At its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback